National Center for Tumor Diseases (NCT) Heidelberg
Dr. Cornelia Jäkel began their work experience in 2013 as a PhD student at the dkfz - German Cancer Research Center, where they focused on Molecular Medicine and achieved a magna cum laude (1,0) distinction. Dr. Cornelia transitioned to the National Center for Tumor Diseases (NCT) Heidelberg in 2017, initially working as a Clinical Trial Coordinator/Research Associate. In April 2018, they were promoted to the role of Head of Clinical Trial Office RadioOncology.
Dr. Cornelia Jäkel began their education at FAU Erlangen-Nürnberg, where they obtained a Bachelor of Science (BS) degree in Molecular Medicine from 2008 to 2011. Dr. Cornelia further pursued their studies in the same field at both FAU Erlangen-Nürnberg and The Johns Hopkins University, earning a Master of Science (MS) degree from both institutions. Dr. Cornelia attended FAU Erlangen-Nürnberg from 2011 to 2013 and The Johns Hopkins University from 2012 to 2013.
In addition to their academic achievements, Dr. Jäkel also obtained certifications in business-related areas. In 2015, they obtained the international Certificate for Business Competence (EBC*L) Level A, specializing in Business Objectives and Management Ratios, Accounting, Costing and Pricing, and Business Law. Furthermore, in 2016, Dr. Jäkel acquired the international Certificate for Business Competence (EBC*L) Level B, focusing on Business Plan, Marketing and Sales, Investment Analysis, Financial Planning, and Financing.
This person is not in any teams
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.